NOW FDA APPROVED

See our press release

© 2025 Abeona Therapeutics Inc. All rights reserved. US-COM-ZEV-250033 03/25

Working together to deliver cell and gene therapies for people impacted by serious diseases

Learn More

Our inspiration

Pipeline


ABO-503

X-Linked Retinoschisis (XLRS)

ABO-503 Current Phase
Preclinical

ABO-504

Stargardt Disease

ABO-504 Current Phase
Preclinical

ABO-505

Autosomal Dominant Optic Atrophy (ADOA)

ABO-505 Current Phase
Preclinical

UX111*

Sanfilippo Syndrome Type A (MPS IIIA)

UX111* Current Phase
Phase 1/2

TSHA-102**

Rett Syndrome

TSHA-102** Current Phase
Phase 1/2

TSHA-118**

Infantile Batten Disease (CLN1 Disease)

TSHA-118** Current Phase
Phase 1/2
Partnered with *Ultragenyx Pharmaceutical Inc.  **Taysha Gene Therapies, Inc.

Manufacturing at The Elisa Linton Center for Rare Disease Therapies